New combo tackles resistant lung cancer in small trial
NCT ID NCT04147351
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a combination of four drugs—atezolizumab, bevacizumab, a platinum drug, and pemetrexed—in 22 people with advanced EGFR-mutant non-small cell lung cancer whose disease had progressed after EGFR-targeted therapy. The goal was to see how many patients' tumors shrank or disappeared. The trial has completed, and results will help determine if this approach is worth further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab (a PD-L1 inhibitor) combined with bevacizumab, carboplatin or cisplatin, and pemetrexed
- What this could lead to
- If successful, this combination could offer a new treatment option for people with EGFR-mutant lung cancer whose tumors have stopped responding to standard targeted therapy.
- What could go wrong
- This is a small, early-phase trial with only 22 participants, so results may not apply to everyone. The combination also carries risks like immune-related side effects and bleeding from bevacizumab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IIIB~IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.